Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Company Info
Contact US
Thryv Therapeutics Inc
Drug Discovery & Development
Overview
Contact US
Contributions
Contributors
Contributions
0 Contributors
1 / 0
1 / 0
1 Contributions
1 / 1
1 / 1
No authors found
FDA
Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
Thryv Therapeutics Inc
PR-09-24-NI-27
Oct 03, 2024
